Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Stock Information for Sutro Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sutro Biopharma Inc.

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 
Sutro Biopharma and Boehringer Ingelheim BioXcellence(TM) collaboration: Established first-in-class cell-free capabilities at commercial scale
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFR?ME-O1 Trial in Platinum Resistant Ovarian Cancer
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Sutro Biopharma Announces Initiation of the Registration-enabling REFR?ME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.